Actively Recruiting
Role of Glucose Metabolism in Migration of Cutaneous Dendritic Cells in Psoriasis
Led by Centre Hospitalier Universitaire de Nice · Updated on 2024-10-15
100
Participants Needed
1
Research Sites
217 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Dendritic cells (DC) paly a key role in the induction and chronicity of psoriasis by capturing the antigenes and activating the T cell repsonse. This activation requires their migration from the cutaneous sensitisation site to the lymph nodes. This migration requires an important intracellular metabolic activity, with a strong involvmenet of glucdic metabolism. This activity is linked with the systemic activity. This study aims to compare the migration and the phenotypic and metabolic caracteristics of blood and skin DCs in patients with or without psoriasis and with or without type 2 diabetes,
CONDITIONS
Official Title
Role of Glucose Metabolism in Migration of Cutaneous Dendritic Cells in Psoriasis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients of both sexes
- Hospitalized in the Dermatology department of the CHU of Nice for moderate to severe psoriasis (PASI ≥ 10)
- Covered by a social security scheme with free and informed consent
- Clinical diagnosis of plaque psoriasis with or without type 2 diabetes (glycated hemoglobin >7%)
- Control group: without psoriasis or other inflammatory skin disease, aged with or without type 2 diabetes (glycated hemoglobin >7%)
You will not qualify if you...
- Minor or unable or unwilling to provide informed consent
- Pregnant or nursing women
- Currently excluded from other biomedical research
- Having generalized chronic inflammatory disease or other inflammatory skin disease
- On corticosteroid, immunomodulator, or immunosuppressant therapy within the last month
- Treated with corticosteroids locally in the last 15 days
- On anti-IL-23 or anti-IL12/23 treatment for less than 3 months
- On anti-IL-17 or anti-TNF treatment for less than 1 month
- Contraindications for skin biopsy (bleeding disorders, anticoagulant use, allergy to xylocaine, history of keloid scars, congenital immune deficiency)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CHU de Nice
Nice, Alpes-maritimes, France, 06001
Actively Recruiting
Research Team
P
PASSERON Thierry, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here